Skip to main content
Equibles
CATX logo

CATX · Perspective Therapeutics, Inc. · Metrics

Track CATX — free

Use CATX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CATX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.19 -0.02 (-1.65%) At close · Oct 27 Q4 2022 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$135.84M
Shares
114.15M
Volume · Oct 27 8.74M Avg daily vol (3M) 1.92M

CATX metrics

79 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.19
Market cap
$135.84M

Price action

20 metrics
Price change (1W)
-44.7%
Price change (30D)
-51.6%
Price change (3M)
-57.1%
Price change (6M)
-71.7%
Price change (YTD)
-56.0%
Price change (1Y)
-59.5%
Trailing year
Price change (5Y)
—
52-week high
$5.65
52-week low
$1.21
Change from 52-week high
-78.6%
Change from 52-week low
+0.0%
Annualized volatility
110.0%
Annualized volatility (3M)
100.8%
Beta
1.7
RSI (14D)
21.4
Price vs SMA 50
-55.8%
Price vs SMA 200
-66.1%
Avg volume (3M)
1.80M
Relative volume
5.3
Average dollar volume
$4.72M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
114.15M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
91.1×
reciprocal yield 1.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
96.3×
reciprocal yield 1.0%
P / book
0.4
reciprocal yield 234.5%
FCF yield
-87.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-84.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
255.4×
reciprocal yield 0.4%
EV / revenue historical average (5Y)
255.4×
reciprocal yield 0.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-01-13

Profitability

9 metrics
Gross margin
100.0%
Operating margin
-2,855.0%
Trailing 12 months
Net margin
-3,243.2%
Gross profit (TTM)
$1.43M
Operating profit (TTM)
−$125.23M
Net income (TTM)
−$116.43M
Trailing 12 months
Diluted EPS (TTM)
$-1.33
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.07
Gross profit per diluted share (TTM)
$0.06
Operating profit per diluted share (TTM)
$-1.43
EBITDA per diluted share (TTM)
$-1.38
Net income per diluted share (TTM)
$-1.33
Operating cash flow per diluted share (TTM)
$-1.03
Free cash flow per diluted share (TTM)
$-1.30
Capital expenditures per diluted share (TTM)
$0.28
R&D per diluted share (TTM)
$1.10
Stock compensation per diluted share (TTM)
$0.11
Book value per share
$2.78

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.43M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+62.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-36.0%
Return on assets
-29.7%
Debt / equity
0.0
Current ratio
6.6
EBITDA (TTM)
−$121.18M
Free cash flow (TTM)
−$121.19M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$235.28M
Latest balance sheet
Cash & equivalents
$48.49M
Total assets
$392.02M
Total debt
$1.60M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$93.07M
Capital expenditures (TTM)
$28.12M
R&D (TTM)
$96.18M
SG&A (TTM)
—
Stock compensation (TTM)
$10.06M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
131
13F filer change QoQ
-8
Institutional ownership
76.5%
Conviction holders (share of 13F filers)
2.3%
Crowding (high-turnover and private-fund holders)
36.5%
Private-fund adviser ownership
36.3%
Active holders' share change QoQ
+0.2%
Holder tenure
8.3
Price vs estimated holder cost
-22.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.2%

Short interest

3 metrics
Short interest
14.6%
Latest settlement · 8.9 days to cover
Days to cover
8.9d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 728387 CUSIP 46489V302 13F (30d) 14 filings 14 filers Visit website Investor relations